NasdaqCM - Nasdaq Real Time Price USD

Tenax Therapeutics, Inc. (TENX)

Compare

5.61

+0.14

(+2.56%)

At close: December 20 at 4:00:01 PM EST

5.59

-0.02

(-0.36%)

After hours: December 20 at 4:49:43 PM EST

Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 17 days ago

TENX
+2.56%
Tenax Therapeutics: Q3 Earnings Snapshot

CHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Wednesday reported a loss of $4 million in its third quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of 19 cents.

Associated Press Finance last month

TENX
+2.56%
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonar

GlobeNewswire last month

TENX
+2.56%
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the compa

GlobeNewswire last month

TENX
+2.56%
TENX: $100 Million Capital Raise

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2024 results on August 13th, 2024 in a press release and through the filing of its Form 10-Q with the SEC. The big news for Tenax has been the impressive capital raise of $100 million in August 2024. Tenax’ $100 million private placement closed one day before

Zacks Small Cap Research 3 months ago

TENX
+2.56%
Tenax Therapeutics: Q2 Earnings Snapshot

CHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Tuesday reported a loss of $3.6 million in its second quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of $1.83.

Associated Press Finance 4 months ago

TENX
+2.56%
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In April, Hosted the KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease CHAPEL HILL, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (“Tenax”) (Nasdaq: TENX)

GlobeNewswire 4 months ago

TENX
+2.56%
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program

• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • Proceeds also will fund the initiation of a second Phase 3 study planned for 2025, shortening timeline to NDA submission; the protocol for this study will be submitted to FDA for comment CHAPEL HILL, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Tenax Ther

GlobeNewswire 4 months ago

TENX
+2.56%
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proc

GlobeNewswire 4 months ago

TENX
+2.56%
TENX: First Quarter Results

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported first quarter 2024 results on May 14th, 2024 in a press release and the filing of its Form 10-Q with the SEC. Since the beginning of the year, the company has enrolled the first patient in the oral levosimendan (TNX-103) LEVEL trial and presented data at a cardiovascular

Zacks Small Cap Research 6 months ago

TENX
+2.56%
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent Recently Hosted KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease Raised Approximately $8 Million of Net Proceeds in R

GlobeNewswire 7 months ago

TENX
+2.56%
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040Expressly provides IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF Expressly provides IP protection for levosimendan in combination with various cardiovascular drugs for use in PH-

GlobeNewswire 7 months ago

TENX
+2.56%
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease Experts will explain pathophysiology of PH-HFpEF, and mechanistic rationale for levosimendan Update on the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for the treatment of PH-HFpEF Tena

GlobeNewswire 8 months ago

TENX
+2.56%
TENX: 2023 Financial Results

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported full year 2023 results on March 28, 2024 in a press release and the filing of its Form 10-K with the SEC. Over the last five months, the company has announced clearance of its investigational new drug (IND) application for clinically advancing oral levosimendan (TNX-103),

Zacks Small Cap Research 8 months ago

TENX
+2.56%
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-HFpEF and for Use in Combination with Other Cardiovascular Therapies The Company Secured Global Commercial Rights to Levosimendan for the Treatment of PH-HFpEFThe Company will host a KOL Event, “LEVEL Setting: Th

GlobeNewswire 8 months ago

TENX
+2.56%
Tenax Therapeutics to Present at the 36th Annual Roth Conference

CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoin

GlobeNewswire 9 months ago

TENX
+2.56%
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) Presentation will occur at Technology and Heart Failure Therapeutics (THT-2024) – in Boston, MA, on March 6, 2024 THT 2024 is an international conference of leading Heart Failure experts focused on innovations in Heart Failure treatment CHAPEL HILL, N.C

GlobeNewswire 9 months ago

TENX
+2.56%
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded rights position Tenax to engage potential global strategic pharmaceutical partners Improved net sales royalty rate structure, now ranging from high single-digit to low-teen percentages. Lowered maximum cost of goodsModified milestone provisions, including additional payment for regulatory approval in Japan, reflect multi-billion dollar global P

GlobeNewswire 9 months ago

TENX
+2.56%
TENX: First Patient Enrolled

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT What’s New? On the heels of a share balance consolidation, Tenax Therapeutics, Inc. (NASDAQ:TENX) began February with a burst of activity. It announced a notice of allowance from the USPTO, the enrollment of its first patient in the LEVEL trial and pricing of $9 million in funds to support clinical efforts. Read on for the

Zacks Small Cap Research 10 months ago

TENX
+2.56%
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of (i) 1,600,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 3,200,000 shares of its common stock (the “Common Warran

GlobeNewswire 10 months ago

TENX
+2.56%

Performance Overview

Return	TENX	S&P 500
YTD	-74.50%	+24.34%
1-Year	-76.07%	+24.38%
3-Year	-99.69%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tenax Therapeutics, Inc. (TENX)

Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely?

Tenax Therapeutics: Q3 Earnings Snapshot

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

TENX: $100 Million Capital Raise

Tenax Therapeutics: Q2 Earnings Snapshot

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

TENX: First Quarter Results

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

TENX: 2023 Financial Results

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

TENX: First Patient Enrolled

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Performance Overview